Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1
is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918.
APG-5918 will be administered orally. It will be supplied in 50 mg and 200 mg tablets.
Patients will be treated in 28-day cycles.